BRAF and neoplasm: Also, in the context of BRAF-mutant CRC, the activation of the MAPK signaling pathway, induced by the BRAF-mutation, may contribute to increased expression of immune evasion-related proteins, such as PD-L1, thereby enhancing the tumor’s vulnerability to immunotherapy.